Administration of attenuated, activated autoimmune T lymphocytes to syngeneic mice and rats has been shown to prevent or induce remission of experimental autoimmune diseases specific for the autoimmune T cells. The process has been termed "T cell vaccination." In a recent study, T cell vaccination was done using T cells sensitized to rat alloantigens. The procedure produced a significant reduction of the mixed lymphocyte reaction (MLR) against allogeneic cells. The reduction in MLR was not specific: Vaccination with T cells specific for stimulator cells of one allotype led to a reduced MLR stimulated by cells of another allotype. The present study was undertaken to examine whether T cell vaccination can induce tolerance to transplantation antigens in vivo. We used the model of heterotopic cardiac transplantation in rats. We now report that vaccinating rats with syngeneic, activated, alloantigen-primed T lymphocytes significantly prolonged survival of rat cardiac allografts. The effect of T cell vaccination was most evident when the T cells had been obtained from rats specifically sensitized against the donor rats: Brown-Norway (BN) allografts in control Wistar rats survived 8. 1993. 91:388-390.)
Introduction
Resistance to a variety of experimental autoimmune diseases in mice and rats can be induced by treating animals with chemically or physically attenuated T lymphocytes that have been specifically activated against the target antigen, a modality termed "T cell vaccination" (1) (2) (3) (4) (5) .
T cell vaccination induces the activation of T helper and T suppressor cells of two types: antiidiotypic T cells directed to the specific T cell vaccine (5, 6) , and T cells reactive to T cell activation markers, the antiergotypic response (7) . Both mechanisms combine to regulate autoimmunity. The results with T cell vaccination in autoimmune diseases led us to evaluate its efficacy in controlling T cell responses to alloantigens; indeed, it was found that T cell vaccination was effective in inhibiting one-way mixed lymphocyte reaction (MLR)' in vitro (8) .
The aim ofthe present study was to examine the effect of T cell vaccination on an alloantigen response in vivo. We used the model ofheterotopic cardiac transplantation in rats. Wistar rats were vaccinated with attenuated T cell vaccines from Wistar rats that had been sensitized against BN alloantigens. Control T cell vaccines were made from mitogen-activated Wistar T cells, or from Wistar T cells sensitized against third party hooded (Ho) rats. The Wistar rats were then grafted with Brown-Norway (BN) hearts.
We found that allospecific T cell vaccination with no other treatment produced a greater than threefold increase in the mean survival of the heart allografts. However, vaccination with T cells primed to third party alloantigens also inhibited rejection to a significant degree.
Methods
Animals. Cardiac transplantation was performed between male inbred Wistar rats (RT1 W) weighing 350-500 g serving as recipients and male inbred BN rats (RT I') weighing 250-350 g serving as donors. Male inbred Ho rats (RT1 C) were used to produce third party T cell vaccines. All rats were obtained from The Animal Breeding Center, Weizmann Institute of Science.
Skin allografting. Full thickness skin grafting was performed as previously described (9) . One male rat served as a donor to up to 10 male recipients. Day of grafting was day 0. The day of rejection was defined as the day on which complete separation of the graft occurred.
Cardiac transplantation. Heterotopic cardiac transplantation was performed under pentobarbital anesthesia (50 mg/kg intraperitoneally), using the modified technique of Ono and Lindsey (10) . Day of grafting was day 0. Graft survival was assessed by daily palpation. The day of rejection was defined as the day of cessation ofheartbeat. Rejection was confirmed histologically. Technical failures within the first 72 h were excluded from the experimental groups.
T cell vaccination. Wistar rats were primed by transplanting BN or Ho skin grafts into the neck region. When the skin allografts were rejected, the draining cervical and axillary lymph nodes were excised and the lymphocytes were stimulated by culture for 48 h with 1.25 gg/ml concanavalin A (Con A) in medium containing antibiotics, 2-mercaptoethanol, and 1% autologous serum as described ( 11 ) . It was previously demonstrated that activation of T cells with Con A in vitro led to a substantial increase in the activity and frequency of T cells specific for antigens to which the rats had been sensitized in vivo ( 12) . Lymph nodes from naive Wistar rats activated with Con A in the same manner served as controls to differentiate between antiergotypic and antiidiotypic responses (7) .
The Wistar anti-BN-, Wistar anti-Ho-, and Con A-activated Wistar lymphocytes were attenuated by treatment for 15 min with 0.3% glutaraldehyde and then washed three times in PBS as described (4) . Wistar rats were vaccinated with three intraperitoneal injections of 2 x I07 vaccinating cells, performed on days -14, -7, and +5 of cardiac transplantation. A fourth vaccination was done on day + 12, when grafts survived that long. In an alternative protocol, instead of skin allografting, Wistar rats were primed by intraperitoneal injection of 5 X 106 BN splenocytes. Mesenteric, cervical, and axillary LN were ex-cised 2 wk later, and the vaccinating lymphocytes were prepared as described above.
Statistics. The Kaplan-Meier method was used to compute actuarial graft survival. The data obtained in each group were expressed as means±SEM, and the Mann-Whitney U test was used for calculation of intergroup significant differences.
Results
Wistar, Brown-Norway, and Hooded rats mutually reject skin grafts. The rat strains in this study were inbred and were derived from standard strains known to be allogenic at the major histocompatibility complex. Nevertheless, we performed skin grafting to confirm the histoincompatibility ofthe rats. Table I shows that Wistar rats rejected BN skin grafts within 16.4±1.5 d and Ho skin grafts within 13.5±1.1 d. BN rejected Ho skin grafts within 13.7±0.1 d. Although it appears that BN skin grafts survived in Wistar rats slightly longer than Ho grafts, the differences did not reach statistical significance. Thus, we may conclude that each ofthe three strains differs substantially from the other two in their major histocompatibility loci.
T cell vaccination prolongs cardiac allograft survival. The results of heart transplantation are shown in Table II Cardiac allograft survival is not influenced by an antiergotype response. As an antiergotypic control, we vaccinated Wistar rats with Con A-activated, syngeneic T cells obtained from naive rats. It was previously shown that such a vaccination can successfully inhibit experimental autoimmune encephalomyelitis in rats by induction of an MHC-non-restricted antiergotypic response (7) . In the present study this type ofvaccination was followed by graft survival of 8.7±0.2 d, virtually identical to the control group (Table II, group 4, Fig. 1) . Thus, the prolongation ofcardiac allograft survival achieved by T cell vaccination was not likely caused by the induction of an antiergotypic response to activation markers on syngeneic T cells.
The effect of T cell vaccination is not MHC-restricted. To examine the antigen specificity of T cell vaccination, Wistar rats were vaccinated with Wistar anti-Ho cells and then transplanted with BN cardiac allografts. The BN heart grafts survived 13.1±0.1 d in these Wistar rats. This degree of survival duced partial, but significant, tolerance to BN rat alloantigens. This lack of specificity cannot be attributed to an antiergotypic response induced by T cell vaccination (7), as vaccination of animals with naive, syngeneic, Con A-activated T cells had no detectable effect on allograft survival. The mechanism by which T cell vaccination inhibits the rejection of cardiac allografts remains to be determined. T cell vaccination against autoimmune disease appears to involve the activation of regulatory T cells that recognize the antigen receptors of the autoimmune T cells (5, 6 ). Vandenbark and his associates have demonstrated that the effect of T cell vaccination against autoimmune encephalomyelitis can be produced by vaccinating Lewis rats with a peptide from the V(3 segment of the T cell receptor (TcR) used by the autoimmune T cells responsible for the disease ( 13 ) . The effective V,3 peptide was obtained from the CDR-II segment ofthe V gene, a segment of the TcR common to all T cells using that V( family irrespective of their antigen specificity ( 13 ) .
Indeed, Offner and her colleagues have shown that regulatory T cells recognizing such a segment of the TcR can inhibit T cells that are reactive to an immunologically different epitope that happens to use a common Vf3 gene ( 14) . Thus, the partial inhibition ofrejection ofBN allografts brought about by an anti-Ho T cell vaccine could be explained if the Wistar T cells to BN and Ho alloantigens used TcR molecules with a similar Vf3 segment. The questions of antiidiotypic regulation and of TcR usage will be more amenable to investigation once we have available the clones of T cells responsible for allograft rejection; at present we can only raise the questions.
Cross-reactivity between some histocompatibility epitopes of BN and Ho rats could also account for partial inhibition of rejection of BN allografts by T cell vaccination with Wistar anti-Ho cells. However, the histocompatibility epitopes of the rat are not at present well enough characterized to resolve this issue. Note that enhancement of survival of kidney allografts may be induced by pretransplant blood transfusion using a third party blood donor (15) . The mechanisms of this effect are also unknown, but may be similar to the effect of T cell vaccination.
Our interest in T cell vaccination in modulating the response to alloantigens stemmed from its successful application in a variety ofexperimental autoimmune diseases (1) (2) (3) (4) (5) . Previously, Binz and Wigzell immunized mice and rats with anti-MHC antibodies in CFA, or with purified MLR-activated T lymphoblasts in CFA ( 16, 17) . They reported MHC-restricted reduction of MLR, cell mediated lymphotoxicity, graft versus host disease, and prolongation of skin allograft survival. They showed induction of antiidiotypic antibodies, as well as autoantiidiotypic killer and suppressor T cells ( 19, 20) . The present study has extended T cell vaccination to cardiac allotransplantation as a model of a vascularized graft. The major difference between our results here and in the MLR (8) , and those reported by Binz and Wigzell concern the degree ofspecificity: In contrast to the nonspecific inhibition we observed, Binz and Wigzell reported no inhibitory effect on a third party allograft after their procedure (16) (17) (18) (19) (20) . The difference in results might be because ofthe different reagents and methods used for vaccination: Binz and Wigzell used either antibodies or T cells generated by in vitro MLR and injected them in CFA (16) (17) (18) (19) (20) ; in contrast, we used the Con A-activated T cells from in vivo primed rats, fixed with a chemical cross-linker, and administered without CFA or other adjuvants. These diverse forms of immunization may have triggered different regulatory mechanisms, resulting in diverse forms of alloantigen unresponsiveness.
Be that as it may, T cell vaccination seems to be an effective therapeutic tool in experimental organ transplantation. The clinical application of this approach remains to be explored.
